Proteomic Analysis of Cerebrospinal Fluid in Canine Cervical Spondylomyelopathy. Issue 9 (1st May 2015)

• Record Type: Journal Article
• Authors: Martin-Vaquero, Paula; da Costa, Ronaldo C.; Allen, Matthew J.; Moore, Sarah A.; Keirsey, Jeremy K.; Green, Kari B.
• Is Part Of: Spine. Volume 40:Issue 9(2015)
• Publication Date: 2015-05-01
• Subjects: Spine -- Abnormalities -- Periodicals; Spine -- Diseases -- Periodicals; Spine -- Surgery -- Periodicals; 616.73005
• DOI: 10.1097/BRS.0000000000000831
• Languages: English
• ISSNs: 0362-2436

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Study Design.</title> <p>Prospective study.</p> </sec> <sec> <title>Objective.</title> <p>To identify proteins with differential expression in the cerebrospinal fluid (CSF) from 15 clinically normal (control) dogs and 15 dogs with cervical spondylomyelopathy (CSM).</p> </sec> <sec> <title>Summary of Background Data.</title> <p>Canine CSM is a spontaneous, chronic, compressive cervical myelopathy similar to human cervical spondylotic myelopathy. There is a limited knowledge of the molecular mechanisms underlying these conditions. Differentially expressed CSF proteins may contribute with novel information about the disease pathogenesis in both dogs and humans.</p> </sec> <sec> <title>Methods.</title> <p>Protein separation was performed with 2-dimensional electrophoresis. A Student <italic>t</italic> test was used to detect significant differences between groups (<italic>P</italic> < 0.05). Three comparisons were made: (1) control <italic>versus</italic> CSM-affected dogs, (2) control <italic>versus</italic> non–corticosteroid-treated CSM-affected dogs, and (3) non–corticosteroid-treated CSM-affected <italic>versus</italic> corticosteroid-treated CSM-affected dogs. Protein spots exhibiting at least a statistically significant 1.25-fold change between groups were selected for subsequent identification with capillary-liquid chromatography tandem mass spectrometry.</p> </sec> <sec> <title>Results.</title> <p>A total of 96 spots had a significant average change of at least 1.25-fold in 1 of the 3 comparisons. Compared with the CSF of control dogs, CSM-affected dogs demonstrated increased CSF expression of 8 proteins including vitamin D-binding protein, gelsolin, creatine kinase B-type, angiotensinogen, α-2-HS-glycoprotein, SPARC (secreted protein, acidic, rich in cysteine), calsyntenin-1, and complement C3, and decreased expression of pigment epithelium-derived factor, prostaglandin-H2 D-isomerase, apolipoprotein E, and clusterin. In the CSF of CSM-affected dogs, corticosteroid treatment increased the expression of haptoglobin, transthyretin isoform 2, cystatin C-like, apolipoprotein E, and clusterin, and decreased the expression of angiotensinogen, α-2-HS-glycoprotein, and gelsolin.</p> </sec> <sec> <title>Conclusion.</title> <p>Many of the differentially expressed proteins are associated with damaged neural tissue, bone turnover, and/or compromised blood-spinal cord barrier. The knowledge of the protein changes that occur in CSM and upon corticosteroid treatment of CSM-affected patients will aid in further understanding the pathomechanisms underlying this disease.</p> <p> <bold>Level of Evidence:</bold> N/A</p> </sec> </abstract>